论文部分内容阅读
最近研究表明能识别和特异性结合红细胞D-抗原的免疫球蛋白(抗D球蛋白,WinRho SDF;Nabi,Boca Raton,FL)对许多特发性血小板减少性紫癜(ITP)患者是一种有效的治疗。还不完全了解其作用机理。给D-阳性患者静脉注射抗D会导致抗体包裹循环红细胞,进而被脾脏首先清除。致敏红细胞的这一免疫介导清除占领了网状内皮系统,使抗体包裹的血小板得以生存。根据临床观察、试验数据和理论计算,ITP抗D疗法的功效取决于数种因素,这些因素影响致敏红细胞数量和脾脏免疫
Recent studies have shown that immunoglobulins (anti-D-globulin, WinRho SDF; Nabi, Boca Raton, FL) that recognize and specifically bind erythrocyte D-antigens are effective for many idiopathic thrombocytopenic purpura (ITP) patients Treatment. Not fully understand its mechanism of action. Intravenous injection of anti-D to a D-positive patient results in the antibody encapsulating circulating red blood cells, which are then first cleared by the spleen. This immune-mediated clearance of sensitized erythrocytes seizes the reticuloendothelial system, allowing antibody-coated platelets to survive. Based on clinical observations, experimental data, and theoretical calculations, the efficacy of ITP anti-D therapy depends on several factors that affect the number of sensitized erythrocytes and spleen immunity